- Leguminous crops as trap crops for Striga hermonthica control under field conditions. 10th World Congress on Parasitic Plants
published in Poster Presentation
- ANTIMICROBIAL ACTIVITY OF THREE MEDICINAL PLANTS
: Background: Medicinal plants have been traditionally used for different kinds of ailments including infectious diseases. Objectives: The present work was undertaken to investigate the antimicrobial activity of three plants used in folk medicine. Methods: Plant extracts of (Quercus infectoria, Glycyrrhiza glabra and Lepidium virginicum) were in vitro tested against four bacterial strains and one type of fungi for their antimicrobial activities by using well diffusion techniques. Results: The ethanolic extracts of these plants showed varying results. Quercus infectoria was found to possess the highly marked antibacterial activity against both E. coli and Staphylococcus aureus while Glycyrrhiza glabra exhibited a significant antibacterial effect against Pseudomonas aurginosa. Lepidium University Of Gezira Journals Of University Of Gezira Gezira Journal of Health Sciences Vol5 No2 Unusual presentation of abdominal tuberculosis Elbashir Gusm Elbari & etal virginicum produced antibacterial activity against E.coli. Both Quercus infectoria and Lepidium virginicum caused a considerable antifungal effect, while Glycyrrhiza glabra devoid of such antifungal activity. Conclusion: The three tested plant extracts could be considered as potential sources of new antimicrobial agents. Further researches should be made to isolate compounds responsible for antimicrobial activities.
published in مجلة الجزيرة للعلوم الصحية
- In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice
: Anti-angiogenesis is an important therapy for cancer treatment. Peptide HM-3 is an integrin antagonist with anti-angiogenic and antitumor activity. Previous research found that HM-3 at an effective dose inhibited tumor growth whereas at higher doses, the inhibitory effect gradually decreased. In the present study, three human tumor cell lines, human colorectal cancer cell (HCT-116) and human hepatic cancer cell (Hep G-2 and SMMC-7721), were selected and their interactions with HM-3 were compared with western blot and flow cytometric assays. The effect of HM-3 on the migration of two tumor cell lines (HCT-116 and Hep G-2) was also evaluated and a bell-shaped dose-efficacy curve was found for both cell lines. Furthermore, in vivo imaging in BALB/c nude mice confirmed that HM-3 had a short half-life and targeted the tumor tissue. Moreover, on an HCT-116 xenograft model in BALB/c nude mice, HM-3 at 3 mg/kg inhibited tumor growth with an inhibition rate of 71.5% (by tumor mass) whereas at 12 and 48 mg/kg, the inhibition rates were 59.2 and 36.0%, respectively. Immunohistochemistry analyses found that both sunitinib (60 mg/kg) and HM-3 (3 and 48 mg/kg) decreased microvascular density and increased percent of HIF-1α and VEGF expressing cells. The present study investigated the effect of tumor microenvironments on the antitumor effect of HM-3 and concluded that HM-3 inhibited angiogenesis and thereafter tumor growth by directly inhibiting HUVEC migration. The special dose-efficacy curves for antitumor effect and for cell migration inhibition were correlated. The present study also confirmed that the effective dose has to be strictly defined for better clinical applications of anti‑angiogenic drugs such as HM-3.
published in Oncol Rep